CN114773487A - 一种流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原及其制备方法 - Google Patents

一种流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原及其制备方法 Download PDF

Info

Publication number
CN114773487A
CN114773487A CN202210606093.7A CN202210606093A CN114773487A CN 114773487 A CN114773487 A CN 114773487A CN 202210606093 A CN202210606093 A CN 202210606093A CN 114773487 A CN114773487 A CN 114773487A
Authority
CN
China
Prior art keywords
asn
val
ser
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202210606093.7A
Other languages
English (en)
Other versions
CN114773487B (zh
Inventor
邓磊
刘德建
衣大龙
刘翠翠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hunan University
Original Assignee
Hunan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunan University filed Critical Hunan University
Priority to CN202210606093.7A priority Critical patent/CN114773487B/zh
Publication of CN114773487A publication Critical patent/CN114773487A/zh
Application granted granted Critical
Publication of CN114773487B publication Critical patent/CN114773487B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/103—Plasmid DNA for invertebrates
    • C12N2800/105—Plasmid DNA for invertebrates for insects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明属于生物技术领域，具体涉及一种流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原及其制备方法。所述疫苗为通过在流感病毒血凝素蛋白引入血凝素单体间二硫键半胱氨酸突变，并与新型冠状病毒蛋白RBD结构域进行融合表达获得的重组蛋白，该HA‑RBD融合蛋白分别与HA和RBD特异性广谱中和抗体具有较好的特异性结合能力，具备成为可以同时预防流感病毒和新型冠病毒的潜在免疫原。

Description

一种流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原及其 制备方法
技术领域
本发明属于生物技术领域，具体涉及一种流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原及其制备方法。
背景技术
接种疫苗仍是预防流感和新冠病毒感染的最有效手段。甲型和乙型流感病毒血凝素HA以三聚体的形式展示在病毒粒子表面，是流感病毒丰度最高的表面糖蛋白，通过与宿主呼吸道上皮细胞糖蛋白或糖脂上的受体末端的唾液酸结合介导病毒进入细胞，并介导内体中病毒与宿主细胞的膜融合，是适应性免疫反应的主要靶点和流感疫苗设计的热点。
SARS-CoV-2通过其表面刺突蛋白S的受体结合域(RBD)与细胞受体血管紧张素转换酶2(ACE2)结合进入靶细胞引发感染。受生物学功能限制，RBD的氨基酸序列和蛋白质结构高度保守，是高效广谱中和抗体的主要靶点，同时也是设计广谱冠状病毒疫苗的重要靶标。
流感病毒和新型冠状病毒都在不断进行突变，在未来新型冠状病毒的预防可能会像流感一样，需要定期接种疫苗提供免疫保护作用，如何实现两种病毒的同时接种，并能产生中和性抗体为当下研究的热点。
发明内容
针对现有技术存在的问题，本发明基于分析流感病毒HA和 SARS-CoV-2S蛋白RBD的晶体结构，合理设计构建可溶性HA-RBD 融合重组蛋白抗原。通过R327Q突变稳定HA的融合前构象；基于已解析的HA晶体结构，通过结构生物学分析设计引入HA单体间的二硫键增加其三聚体稳定性，并分别与SARS-CoV-2S蛋白RBD结构域融合表达，分别通过变性还原和变性非还原条件的SDS-PAGE 考马斯亮蓝染色和Western Blot分析HA-RBD融合蛋白的表达和三聚体比例，通过ELISA分析HA-RBD融合蛋白分别与HA和RBD特异性广谱中和抗体的结合能力评价其抗原性。
为实现上述发明目的，本发明提供了一种流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原，所述疫苗免疫原为通过在流感病毒血凝素蛋白引入血凝素单体间二硫键半胱氨酸突变，并与新型冠状病毒蛋白RBD结构域进行融合表达获得的重组蛋白。
进一步的，所述流感病毒包括但不限于毒株A/Washington/5/2011 (H1N1)、毒株A/New Caledonia/20/1999(H1N1)和与所述毒株 A/Washington/5/2011(H1N1)、毒株A/NewCaledonia/20/1999(H1N1) 的氨基酸序列具有89％以上同源性的毒株。
进一步的，所述毒株A/Washington/5/2011(H1N1)的突变位点 L20C-K47C。
所述毒株A/New Caledonia/20/1999(H1N1)的突变位点 L24C-G47C。
进一步的，所述流感病毒和新型冠状病毒融合重组亚单位疫苗的氨基酸序列如SEQ ID NO:2和SEQ ID NO:4所示。
基于同一发明构思的，本发明实施例还提供了一种流感病毒和新型冠状病毒融合重组蛋白疫苗，所述疫苗包括上述流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原；
所述疫苗还包括疫苗载体，所述疫苗载体包括：DNA载体、 mRNA载体、水凝胶载体、脱溶剂纳米颗粒载体、蛋白质自组装纳米颗粒载体、腺病毒载体、慢病毒载体、植物病毒载体、减毒人感染病毒载体、人感染复制缺陷型病毒载体，以及破伤风类毒素、白喉类毒素、白喉毒素的无毒变异体、B群脑膜炎球菌外膜蛋白复合体、白介素、病原相关分子模式、损伤相关分子模式融合蛋白载体。
基于同一发明构思的，本发明实施例还提供了一种流感病毒和新型冠状病毒融合重组亚单位疫苗的制备方法，所述制备方法具体包括以下步骤：
将甲型流感病毒HA的信号肽序列进行置换成昆虫细胞蜂毒素信号肽序列，并在HA胞外基因序列的羧基端添加切割位点和亲和纯化标签序列，依据昆虫细胞宿主优化密码子，合成在pFastBac1载体中，获得带有甲型流感病毒HA序列的重组质粒；
在所述带有甲型流感病毒HA序列的重组质粒的HA胞外域基因序列引入单体间半胱氨酸突变获得HA突变体的pFastBac1重组质粒；
将SARS-CoV-2W-1病毒株的S蛋白昆虫细胞表达质粒与所述 HA突变体的pFastBac1重组质粒通过Overlap PCR的方法制备融合的昆虫细胞重组表达质粒；
利用bac-to-bac昆虫杆状病毒表达系统表达所述融合的昆虫细胞重组表达质粒并纯化获得HA-RBD重组蛋白。
进一步的，所述切割位点包括：Factor Xa切割位点、凝血酶裂解位点、HRV 3C蛋白酶切位点、TEV蛋白酶切位点、肠激酶切位点、 SUMO蛋白酶切位点；
所述标签序列包括：6×His标签、HA标签、FLAG标签、谷胱甘肽巯基转移酶标签、麦芽糖结合蛋白标签、NusA标签、SUMO标签、Strep-tag标签。
进一步的，所述利用bac-to-bac昆虫杆状病毒表达系统表达所述融合的昆虫细胞重组表达质粒并纯化获得HA-RBD重组蛋白过程具体包括：
将融合的昆虫细胞重组表达质粒转染sf9昆虫细胞，进行培养获得生长状态良好的细胞后进行扩大培养，离心收集上清液；
将所述上清液进行过滤后，并采用亲和树脂层析法进行纯化并进一步洗脱置换，获得HA-RBD重组蛋白。
有益效果：
本发明依据蛋白质结构信息和辅助软件分析结果，通过结构生物学分析在HA单体间引入二硫键，增加其三聚体稳定性，再与 SARS-CoV-2S蛋白RBD结构域融合表达，获得可溶性HA-RBD融合重组蛋白抗原，且该HA-RBD融合蛋白分别与HA和RBD特异性广谱中和抗体具有较好的特异性结合能力，具备成为可以同时预防流感病毒和新型冠病毒的潜在免疫原。
附图说明
图1为本发明实施例提供的HA-RBD重组蛋白构建的基因克隆示意图；
图2为本发明实施例提供的SDS-PAGE考马斯亮蓝染色和 Westernblot检测HA-RBD重组蛋白纯化的分析图；
图3为本发明实施例提供的ELISA检测HA-RBD重组蛋白分别与CR9114和FISW84等识别HA柄部表位广谱中和单克隆抗体的结合能力图；
图4为本发明实施例提供的ELISA检测HA-RBD重组蛋白分别与S309、CR3022、P2B-2F6和B38等识别SARS-CoV-2S蛋白RBD 表位广谱中和单克隆抗体的结合能力图。
具体实施方式
为使本发明要解决的技术问题、技术方案和优点更加清楚，下面将结合具体实施例进行详细描述，但本发明的保护范围并不限于以下具体实施例。
除非另有定义，下文中所使用的所有专业术语与本领域技术人员通常理解含义相同。本文中所使用的专业术语只是为了描述具体实施例的目的，并不是旨在限制本发明的保护范围。
除非另有特别说明，本发明中用到的各种原材料、试剂、仪器和设备等均可通过市场购买得到或者可通过现有方法制备得到。
在本发明实施例中，SARS-CoV-2W-1病毒株的S蛋白昆虫细胞表达质粒由湖南大学葛行义教授馈赠，昆虫细胞sf9购买于ATCC。特异性结合SARS-CoV-2S蛋白RBD的广谱中和抗体S309、 CR3022、P2B-2F6和B38等由中山大学陈耀庆教授馈赠。
实施例1
构建HA-RBD昆虫细胞重组表达质粒
以A/Washington/2011(H1N1)和A/New Caledonia/1999(H1N1)病毒为例，将A/Washington/2011(H1N1)和A/New Caledonia/1999(H1N1) 病毒HA的信号肽序列置换为昆虫细胞蜂毒素信号肽序列，羧基端添加FactorXa切割位点和6×His标签序列，按照昆虫细胞密码子优化后合成在pFastBac 1载体中，获得pFastBac1-WA11和pFastBac1- NC99胞外域质粒。以合成的pFastBac1-WA11胞外域质粒突变 R327Q，接着引入1对单体间半胱氨酸突变组合，包括点突变 L20C-K47C获得WA11 Mut；以合成的pFastBac1-NC99胞外域质粒突变R327Q，接着引入1对单体间半胱氨酸突变组合，包括 L24C-G47C获得NC99 Mut。上述突变均按照
Figure RE-GDA0003708054300000051
Site-Directed Mutagenesis Kit(NEB,E0554S)说明书操作。将pFastBac1-WA11、 pFastBac1-NC99、WA11 Mut、NC99 Mut分别与SARS-CoV-2W-1 病毒株的S蛋白昆虫细胞表达质粒通过Overlap PCR的方法【Hilgarth, R.S.,and Lanigan,T.M.(2020).Optimization ofoverlap extension PCR for efficient transgeneconstruction.MethodsX 7,100759】构建多种HA基因片段与RBD 基因片段融合的昆虫细胞重组表达质粒pFastBac 1-HA-RBD质粒。
实施例2
HA-RBD重组蛋白的表达与纯化
利用
Figure RE-GDA0003708054300000061
II转染试剂(Gibco)将多种pFastBac 1-HA-RBD 质粒分别转染sf9昆虫细胞，27℃条件下，昆虫细胞在SF-SFM昆虫细胞无血清培养基中静置培养72小时；培养上清液接种生长状态良好的sf9细胞，27℃，110rpm/min条件下，sf9细胞在SF-SFM无血清培养基中震荡培养72h后离心收集培养上清液；继续接种sf9细胞，在27℃，110rpm/min条件下扩大培养，72小时后离心收集培养上清液，经0.45μm滤器过滤后，利用6×His标签亲和层析树脂纯化HA-RBD重组蛋白，利用30kDa超滤管(Millipore)蛋白质洗脱液置换为PBS，离心浓缩后加入20％甘油，-80℃保存。获得多种HA-RBD 重组蛋白，具体为：WA11-RBD、WA11Mut-RBD、NC99-RBD、NC99 Mut-RBD，氨基酸序列如SEQ ID NO:1、2、3、4。
另外SARS-CoV-2S蛋白RBD氨基酸序列为： MKFLVNVALVFMVVYISYIYARVQPTESIVRFPN ITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTF KCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYN YKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFER DISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVV VLSFELLHAPATVCGPKKSTNLVKNKCVNFNIEGRHHHHHH。
A/Washington/5/2011(H1N1)野生型HA的氨基酸序列如序列表为： MKFLVNVALVFMVVYISYIYADTLCIGYHANNSTDTVDTVLEKNV TVTHSVNLLEDKHNGKLCKLRGVAPLHLGKCNIAGWILGNPECES LSTASSWSYIVETSSSDNGTCYPGDFIDYEELREQLSSVSSFERFEIF PKTSSWPNHDSNKGVTAACPHAGAKGFYKNLIWLVKKGNSYPKL SKSYINDKGKEVLVLWGIHHPSTTADQQSLYQNADTYVFVGTSRY SKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVVP RYAFAMERNAGSGIIISDTPVHDCNTTCQTPKGAINTSLPFQNIHPIT IGKCPKYVKSTKLRLATGLRNVPSIQSRGLFGAIAGFIEGGWTGM VDGWYGYHHQNEQGSGYAADLKSTQNAIDKITNKVNSVIEKMN TQFTAVGKEFNHLEKRIENLNKKVDDGFLDIWTYNAELLVLLENE RTLDYHDSNVKNLYEKVRNQLKNNAKEIGNGCFEFYHKCDNTC MESVKNGTYDYPKYSEEAKLNREEIDGVKLESTRIYQIEGRHHHH HH。
A/New Caledonia/20/1999(H1N1)野生型H1的氨基酸序列如序列表为： MKFLVNVALVFMVVYISYIYADTICIGYHANNSTDTVDTVLEKNV TVTHSVNLLEDSHNGKLCLLKGIAPLQLGNCSVAGWILGNPECEL LISKESWSYIVETPNPENGTCYPGYFADYEELREQLSSVSSFERFEI FPKESSWPNHTVTGVSASCSHNGKSSFYRNLLWLTGKNGLYPNLS KSYVNNKEKEVLVLWGVHHPPNIGNQRALYHTENAYVSVVSSHY SRRFTPEIAKRPKVRDQEGRINYYWTLLEPGDTIIFEANGNLIAPW YAFALSRGFGSGIITSNAPMDECDAKCQTPQGAINSSLPFQNVHPV TIGECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGM VDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNSVIEKMN TQFTAVGKEFNKLERRMENLNKKVDDGFLDIWTYNAELLVLLEN ERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCNNEC MESVKNGTYDYPKYSEESKLNREKIDGVKLESMGVYQIEGRHHH HHH。
实施例3
SDS-PAGE和WesternBlot分析
在SDS、DTT变性还原和SDS变性非还原条件下对HA-RBD重组蛋白进行10％聚丙烯酰胺SDS-PAGE电泳分析，将蛋白样品转印到PVDF膜上，10％脱脂牛奶(TBS中含0.05％的吐温-20，TBST) 室温封闭2小时，His标签鼠源单克隆抗体室温孵育2h，TBST洗涤 3遍后，室温孵育羊抗鼠二抗1h，TBST洗涤3遍后，使用ECL化学发光液(Bio-Rad)进行显影曝光。
实施例4
ELISA检测HA-RBD融合蛋白与广谱中和抗体的结合能力
为了检测HA-RBD融合蛋白与特异性识别HA柄部的广谱中和抗体CR9114和FISW84以及特异性识别SARS-CoV-2S蛋白RBD 的广谱中和抗体S309、CR3022、P2B-2F6和B38的结合能力，将 100ng/孔的可溶性HA-RBD、HA、RBD重组蛋白和BSA包被到ELISA 反应板中，4℃过夜；PBST(PBS含0.05％吐温-20)洗涤孔板后，用封闭液(含5％脱脂牛奶PBS)室温封闭1.5h,用PBST洗涤后，加入封闭液倍比稀释的HA和RBD广谱中和抗体(初始浓度5μg/ml, 5倍倍比稀释)，室温孵育1h；用PBST洗涤3遍后，羊抗人抗体1： 5000稀释后室温孵育1h,用PBST洗3遍后，避光加入TMB单组份显色液，37℃孵育10min后加入等体积的1M H2SO4终止反应。用酶标仪测定OD450 nm处的吸光值。
结果分析
如图1所示，其为HA-RBD重组抗原基因构建示意图，昆虫细胞表达载体pFastBac 1的PH启动子之后依次串联表达蜂毒素信号肽基因、HA胞外域基因片段、SARS-CoV-2S蛋白RBD基因片段、 FactorXa切割位点和6×His标签序列。
SDS-PAGE考马斯亮蓝染色和Western Blot鉴定HA-RBD重组抗原
如图2所示，NC99-RBD、NC99 Mut-RBD、WA11-RBD和WA11 Mut-RBD融合重组蛋白均表达成功，SDS变性和DTT还原条件下，各个HA-RBD融合重组蛋白的单体条带纯度均较高；SDS变性非还原条件下，各个HA-RBD融合重组蛋白均检测到一定比例的三聚体条带，相较于NC99-RBD和WA11-RBD融合重组蛋白，NC99 Mut-RBD和WA11 Mut-RBD融合重组蛋白中三聚体形式蛋白所占比例均有一定程度的提高。
HA-RBD融合蛋白与HA和RBD广谱中和抗体具有较好的特异性结合能力
WA11-RBD、WA11 Mut-RBD、NC99-RBD和NC99 Mut-RBD融合重组蛋白与HA柄部特异性广谱中和抗体CR9114和FISW84(图 3)，以及SARS-CoV-2S蛋白RBD特异性广谱中和抗体S309、 CR3022、P2B-2F6和B38等(图4)均能较好的特异性结合,表明上述HA-RBD融合重组蛋白中HA和RBD的抗原性均保持完好，提示上述HA-RBD融合重组蛋白具备成为可以同时预防流感病毒和新型冠病毒的潜在免疫原。
在其他氨基酸突变、添加或减少等操作的情况下，如果未显著提升融合蛋白的抗原性，仍受本专利保护。
以上所述实施例，仅为本发明较佳的具体实施方式，但本发明的保护范围并不局限于此，任何熟悉本技术领域的技术人员在本发明的技术范围内，根据本发明的技术方案及其构思加以等同替换或改变，都应涵盖在本发明的保护范围内。
序列表
<110> 湖南大学
<120> 一种流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原及其制备方法
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 767
<212> PRT
<213> WA11-RBD
<400> 1
Met Lys Phe Leu Val Asn Val Ala Leu Val Phe Met Val Val Tyr Ile
1 5 10 15
Ser Tyr Ile Tyr Ala Asp Thr Leu Cys Ile Gly Tyr His Ala Asn Asn
20 25 30
Ser Thr Asp Thr Val Asp Thr Val Leu Glu Lys Asn Val Thr Val Thr
35 40 45
His Ser Val Asn Leu Leu Glu Asp Lys His Asn Gly Lys Leu Cys Lys
50 55 60
Leu Arg Gly Val Ala Pro Leu His Leu Gly Lys Cys Asn Ile Ala Gly
65 70 75 80
Trp Ile Leu Gly Asn Pro Glu Cys Glu Ser Leu Ser Thr Ala Ser Ser
85 90 95
Trp Ser Tyr Ile Val Glu Thr Ser Ser Ser Asp Asn Gly Thr Cys Tyr
100 105 110
Pro Gly Asp Phe Ile Asp Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser
115 120 125
Val Ser Ser Phe Glu Arg Phe Glu Ile Phe Pro Lys Thr Ser Ser Trp
130 135 140
Pro Asn His Asp Ser Asn Lys Gly Val Thr Ala Ala Cys Pro His Ala
145 150 155 160
Gly Ala Lys Gly Phe Tyr Lys Asn Leu Ile Trp Leu Val Lys Lys Gly
165 170 175
Asn Ser Tyr Pro Lys Leu Ser Lys Ser Tyr Ile Asn Asp Lys Gly Lys
180 185 190
Glu Val Leu Val Leu Trp Gly Ile His His Pro Ser Thr Thr Ala Asp
195 200 205
Gln Gln Ser Leu Tyr Gln Asn Ala Asp Thr Tyr Val Phe Val Gly Thr
210 215 220
Ser Arg Tyr Ser Lys Lys Phe Lys Pro Glu Ile Ala Ile Arg Pro Lys
225 230 235 240
Val Arg Asp Gln Glu Gly Arg Met Asn Tyr Tyr Trp Thr Leu Val Glu
245 250 255
Pro Gly Asp Lys Ile Thr Phe Glu Ala Thr Gly Asn Leu Val Val Pro
260 265 270
Arg Tyr Ala Phe Ala Met Glu Arg Asn Ala Gly Ser Gly Ile Ile Ile
275 280 285
Ser Asp Thr Pro Val His Asp Cys Asn Thr Thr Cys Gln Thr Pro Lys
290 295 300
Gly Ala Ile Asn Thr Ser Leu Pro Phe Gln Asn Ile His Pro Ile Thr
305 310 315 320
Ile Gly Lys Cys Pro Lys Tyr Val Lys Ser Thr Lys Leu Arg Leu Ala
325 330 335
Thr Gly Leu Arg Asn Val Pro Ser Ile Gln Ser Arg Gly Leu Phe Gly
340 345 350
Ala Ile Ala Gly Phe Ile Glu Gly Gly Trp Thr Gly Met Val Asp Gly
355 360 365
Trp Tyr Gly Tyr His His Gln Asn Glu Gln Gly Ser Gly Tyr Ala Ala
370 375 380
Asp Leu Lys Ser Thr Gln Asn Ala Ile Asp Lys Ile Thr Asn Lys Val
385 390 395 400
Asn Ser Val Ile Glu Lys Met Asn Thr Gln Phe Thr Ala Val Gly Lys
405 410 415
Glu Phe Asn His Leu Glu Lys Arg Ile Glu Asn Leu Asn Lys Lys Val
420 425 430
Asp Asp Gly Phe Leu Asp Ile Trp Thr Tyr Asn Ala Glu Leu Leu Val
435 440 445
Leu Leu Glu Asn Glu Arg Thr Leu Asp Tyr His Asp Ser Asn Val Lys
450 455 460
Asn Leu Tyr Glu Lys Val Arg Asn Gln Leu Lys Asn Asn Ala Lys Glu
465 470 475 480
Ile Gly Asn Gly Cys Phe Glu Phe Tyr His Lys Cys Asp Asn Thr Cys
485 490 495
Met Glu Ser Val Lys Asn Gly Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu
500 505 510
Glu Ala Lys Leu Asn Arg Glu Glu Ile Asp Gly Val Lys Leu Glu Ser
515 520 525
Thr Arg Ile Tyr Gln Arg Val Gln Pro Thr Glu Ser Ile Val Arg Phe
530 535 540
Pro Asn Ile Thr Asn Leu Cys Pro Phe Gly Glu Val Phe Asn Ala Thr
545 550 555 560
Arg Phe Ala Ser Val Tyr Ala Trp Asn Arg Lys Arg Ile Ser Asn Cys
565 570 575
Val Ala Asp Tyr Ser Val Leu Tyr Asn Ser Ala Ser Phe Ser Thr Phe
580 585 590
Lys Cys Tyr Gly Val Ser Pro Thr Lys Leu Asn Asp Leu Cys Phe Thr
595 600 605
Asn Val Tyr Ala Asp Ser Phe Val Ile Arg Gly Asp Glu Val Arg Gln
610 615 620
Ile Ala Pro Gly Gln Thr Gly Lys Ile Ala Asp Tyr Asn Tyr Lys Leu
625 630 635 640
Pro Asp Asp Phe Thr Gly Cys Val Ile Ala Trp Asn Ser Asn Asn Leu
645 650 655
Asp Ser Lys Val Gly Gly Asn Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg
660 665 670
Lys Ser Asn Leu Lys Pro Phe Glu Arg Asp Ile Ser Thr Glu Ile Tyr
675 680 685
Gln Ala Gly Ser Thr Pro Cys Asn Gly Val Glu Gly Phe Asn Cys Tyr
690 695 700
Phe Pro Leu Gln Ser Tyr Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr
705 710 715 720
Gln Pro Tyr Arg Val Val Val Leu Ser Phe Glu Leu Leu His Ala Pro
725 730 735
Ala Thr Val Cys Gly Pro Lys Lys Ser Thr Asn Leu Val Lys Asn Lys
740 745 750
Cys Val Asn Phe Asn Ile Glu Gly Arg His His His His His His
755 760 765
<210> 2
<211> 767
<212> PRT
<213> WA11 Mut-RBD
<400> 2
Met Lys Phe Leu Val Asn Val Ala Leu Val Phe Met Val Val Tyr Ile
1 5 10 15
Ser Tyr Ile Tyr Ala Asp Thr Leu Cys Ile Gly Tyr His Ala Asn Asn
20 25 30
Ser Thr Asp Thr Val Asp Thr Val Cys Glu Lys Asn Val Thr Val Thr
35 40 45
His Ser Val Asn Leu Leu Glu Asp Lys His Asn Gly Lys Leu Cys Lys
50 55 60
Leu Arg Gly Val Ala Pro Leu His Leu Gly Lys Cys Asn Ile Ala Gly
65 70 75 80
Trp Ile Leu Gly Asn Pro Glu Cys Glu Ser Leu Ser Thr Ala Ser Ser
85 90 95
Trp Ser Tyr Ile Val Glu Thr Ser Ser Ser Asp Asn Gly Thr Cys Tyr
100 105 110
Pro Gly Asp Phe Ile Asp Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser
115 120 125
Val Ser Ser Phe Glu Arg Phe Glu Ile Phe Pro Lys Thr Ser Ser Trp
130 135 140
Pro Asn His Asp Ser Asn Lys Gly Val Thr Ala Ala Cys Pro His Ala
145 150 155 160
Gly Ala Lys Gly Phe Tyr Lys Asn Leu Ile Trp Leu Val Lys Lys Gly
165 170 175
Asn Ser Tyr Pro Lys Leu Ser Lys Ser Tyr Ile Asn Asp Lys Gly Lys
180 185 190
Glu Val Leu Val Leu Trp Gly Ile His His Pro Ser Thr Thr Ala Asp
195 200 205
Gln Gln Ser Leu Tyr Gln Asn Ala Asp Thr Tyr Val Phe Val Gly Thr
210 215 220
Ser Arg Tyr Ser Lys Lys Phe Lys Pro Glu Ile Ala Ile Arg Pro Lys
225 230 235 240
Val Arg Asp Gln Glu Gly Arg Met Asn Tyr Tyr Trp Thr Leu Val Glu
245 250 255
Pro Gly Asp Lys Ile Thr Phe Glu Ala Thr Gly Asn Leu Val Val Pro
260 265 270
Arg Tyr Ala Phe Ala Met Glu Arg Asn Ala Gly Ser Gly Ile Ile Ile
275 280 285
Ser Asp Thr Pro Val His Asp Cys Asn Thr Thr Cys Gln Thr Pro Lys
290 295 300
Gly Ala Ile Asn Thr Ser Leu Pro Phe Gln Asn Ile His Pro Ile Thr
305 310 315 320
Ile Gly Lys Cys Pro Lys Tyr Val Lys Ser Thr Lys Leu Arg Leu Ala
325 330 335
Thr Gly Leu Arg Asn Val Pro Ser Ile Gln Ser Gln Gly Leu Phe Gly
340 345 350
Ala Ile Ala Gly Phe Ile Glu Gly Gly Trp Thr Gly Met Val Asp Gly
355 360 365
Trp Tyr Gly Tyr His His Gln Asn Glu Gln Gly Ser Gly Tyr Ala Ala
370 375 380
Asp Leu Lys Ser Thr Gln Asn Ala Ile Asp Cys Ile Thr Asn Lys Val
385 390 395 400
Asn Ser Val Ile Glu Lys Met Asn Thr Gln Phe Thr Ala Val Gly Lys
405 410 415
Glu Phe Asn His Leu Glu Lys Arg Ile Glu Asn Leu Asn Lys Lys Val
420 425 430
Asp Asp Gly Phe Leu Asp Ile Trp Thr Tyr Asn Ala Glu Leu Leu Val
435 440 445
Leu Leu Glu Asn Glu Arg Thr Leu Asp Tyr His Asp Ser Asn Val Lys
450 455 460
Asn Leu Tyr Glu Lys Val Arg Asn Gln Leu Lys Asn Asn Ala Lys Glu
465 470 475 480
Ile Gly Asn Gly Cys Phe Glu Phe Tyr His Lys Cys Asp Asn Thr Cys
485 490 495
Met Glu Ser Val Lys Asn Gly Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu
500 505 510
Glu Ala Lys Leu Asn Arg Glu Glu Ile Asp Gly Val Lys Leu Glu Ser
515 520 525
Thr Arg Ile Tyr Gln Arg Val Gln Pro Thr Glu Ser Ile Val Arg Phe
530 535 540
Pro Asn Ile Thr Asn Leu Cys Pro Phe Gly Glu Val Phe Asn Ala Thr
545 550 555 560
Arg Phe Ala Ser Val Tyr Ala Trp Asn Arg Lys Arg Ile Ser Asn Cys
565 570 575
Val Ala Asp Tyr Ser Val Leu Tyr Asn Ser Ala Ser Phe Ser Thr Phe
580 585 590
Lys Cys Tyr Gly Val Ser Pro Thr Lys Leu Asn Asp Leu Cys Phe Thr
595 600 605
Asn Val Tyr Ala Asp Ser Phe Val Ile Arg Gly Asp Glu Val Arg Gln
610 615 620
Ile Ala Pro Gly Gln Thr Gly Lys Ile Ala Asp Tyr Asn Tyr Lys Leu
625 630 635 640
Pro Asp Asp Phe Thr Gly Cys Val Ile Ala Trp Asn Ser Asn Asn Leu
645 650 655
Asp Ser Lys Val Gly Gly Asn Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg
660 665 670
Lys Ser Asn Leu Lys Pro Phe Glu Arg Asp Ile Ser Thr Glu Ile Tyr
675 680 685
Gln Ala Gly Ser Thr Pro Cys Asn Gly Val Glu Gly Phe Asn Cys Tyr
690 695 700
Phe Pro Leu Gln Ser Tyr Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr
705 710 715 720
Gln Pro Tyr Arg Val Val Val Leu Ser Phe Glu Leu Leu His Ala Pro
725 730 735
Ala Thr Val Cys Gly Pro Lys Lys Ser Thr Asn Leu Val Lys Asn Lys
740 745 750
Cys Val Asn Phe Asn Ile Glu Gly Arg His His His His His His
755 760 765
<210> 3
<211> 766
<212> PRT
<213> NC99-RBD
<400> 3
Met Lys Phe Leu Val Asn Val Ala Leu Val Phe Met Val Val Tyr Ile
1 5 10 15
Ser Tyr Ile Tyr Ala Asp Thr Ile Cys Ile Gly Tyr His Ala Asn Asn
20 25 30
Ser Thr Asp Thr Val Asp Thr Val Leu Glu Lys Asn Val Thr Val Thr
35 40 45
His Ser Val Asn Leu Leu Glu Asp Ser His Asn Gly Lys Leu Cys Leu
50 55 60
Leu Lys Gly Ile Ala Pro Leu Gln Leu Gly Asn Cys Ser Val Ala Gly
65 70 75 80
Trp Ile Leu Gly Asn Pro Glu Cys Glu Leu Leu Ile Ser Lys Glu Ser
85 90 95
Trp Ser Tyr Ile Val Glu Thr Pro Asn Pro Glu Asn Gly Thr Cys Tyr
100 105 110
Pro Gly Tyr Phe Ala Asp Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser
115 120 125
Val Ser Ser Phe Glu Arg Phe Glu Ile Phe Pro Lys Glu Ser Ser Trp
130 135 140
Pro Asn His Thr Val Thr Gly Val Ser Ala Ser Cys Ser His Asn Gly
145 150 155 160
Lys Ser Ser Phe Tyr Arg Asn Leu Leu Trp Leu Thr Gly Lys Asn Gly
165 170 175
Leu Tyr Pro Asn Leu Ser Lys Ser Tyr Val Asn Asn Lys Glu Lys Glu
180 185 190
Val Leu Val Leu Trp Gly Val His His Pro Pro Asn Ile Gly Asn Gln
195 200 205
Arg Ala Leu Tyr His Thr Glu Asn Ala Tyr Val Ser Val Val Ser Ser
210 215 220
His Tyr Ser Arg Arg Phe Thr Pro Glu Ile Ala Lys Arg Pro Lys Val
225 230 235 240
Arg Asp Gln Glu Gly Arg Ile Asn Tyr Tyr Trp Thr Leu Leu Glu Pro
245 250 255
Gly Asp Thr Ile Ile Phe Glu Ala Asn Gly Asn Leu Ile Ala Pro Trp
260 265 270
Tyr Ala Phe Ala Leu Ser Arg Gly Phe Gly Ser Gly Ile Ile Thr Ser
275 280 285
Asn Ala Pro Met Asp Glu Cys Asp Ala Lys Cys Gln Thr Pro Gln Gly
290 295 300
Ala Ile Asn Ser Ser Leu Pro Phe Gln Asn Val His Pro Val Thr Ile
305 310 315 320
Gly Glu Cys Pro Lys Tyr Val Arg Ser Ala Lys Leu Arg Met Val Thr
325 330 335
Gly Leu Arg Asn Ile Pro Ser Ile Gln Ser Arg Gly Leu Phe Gly Ala
340 345 350
Ile Ala Gly Phe Ile Glu Gly Gly Trp Thr Gly Met Val Asp Gly Trp
355 360 365
Tyr Gly Tyr His His Gln Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp
370 375 380
Gln Lys Ser Thr Gln Asn Ala Ile Asn Gly Ile Thr Asn Lys Val Asn
385 390 395 400
Ser Val Ile Glu Lys Met Asn Thr Gln Phe Thr Ala Val Gly Lys Glu
405 410 415
Phe Asn Lys Leu Glu Arg Arg Met Glu Asn Leu Asn Lys Lys Val Asp
420 425 430
Asp Gly Phe Leu Asp Ile Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu
435 440 445
Leu Glu Asn Glu Arg Thr Leu Asp Phe His Asp Ser Asn Val Lys Asn
450 455 460
Leu Tyr Glu Lys Val Lys Ser Gln Leu Lys Asn Asn Ala Lys Glu Ile
465 470 475 480
Gly Asn Gly Cys Phe Glu Phe Tyr His Lys Cys Asn Asn Glu Cys Met
485 490 495
Glu Ser Val Lys Asn Gly Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu Glu
500 505 510
Ser Lys Leu Asn Arg Glu Lys Ile Asp Gly Val Lys Leu Glu Ser Met
515 520 525
Gly Val Tyr Gln Arg Val Gln Pro Thr Glu Ser Ile Val Arg Phe Pro
530 535 540
Asn Ile Thr Asn Leu Cys Pro Phe Gly Glu Val Phe Asn Ala Thr Arg
545 550 555 560
Phe Ala Ser Val Tyr Ala Trp Asn Arg Lys Arg Ile Ser Asn Cys Val
565 570 575
Ala Asp Tyr Ser Val Leu Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys
580 585 590
Cys Tyr Gly Val Ser Pro Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn
595 600 605
Val Tyr Ala Asp Ser Phe Val Ile Arg Gly Asp Glu Val Arg Gln Ile
610 615 620
Ala Pro Gly Gln Thr Gly Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro
625 630 635 640
Asp Asp Phe Thr Gly Cys Val Ile Ala Trp Asn Ser Asn Asn Leu Asp
645 650 655
Ser Lys Val Gly Gly Asn Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys
660 665 670
Ser Asn Leu Lys Pro Phe Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln
675 680 685
Ala Gly Ser Thr Pro Cys Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe
690 695 700
Pro Leu Gln Ser Tyr Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln
705 710 715 720
Pro Tyr Arg Val Val Val Leu Ser Phe Glu Leu Leu His Ala Pro Ala
725 730 735
Thr Val Cys Gly Pro Lys Lys Ser Thr Asn Leu Val Lys Asn Lys Cys
740 745 750
Val Asn Phe Asn Ile Glu Gly Arg His His His His His His
755 760 765
<210> 4
<211> 766
<212> PRT
<213> NC99 Mut-RBD
<400> 4
Met Lys Phe Leu Val Asn Val Ala Leu Val Phe Met Val Val Tyr Ile
1 5 10 15
Ser Tyr Ile Tyr Ala Asp Thr Ile Cys Ile Gly Tyr His Ala Asn Asn
20 25 30
Ser Thr Asp Thr Val Asp Thr Val Cys Glu Lys Asn Val Thr Val Thr
35 40 45
His Ser Val Asn Leu Leu Glu Asp Ser His Asn Gly Lys Leu Cys Leu
50 55 60
Leu Lys Gly Ile Ala Pro Leu Gln Leu Gly Asn Cys Ser Val Ala Gly
65 70 75 80
Trp Ile Leu Gly Asn Pro Glu Cys Glu Leu Leu Ile Ser Lys Glu Ser
85 90 95
Trp Ser Tyr Ile Val Glu Thr Pro Asn Pro Glu Asn Gly Thr Cys Tyr
100 105 110
Pro Gly Tyr Phe Ala Asp Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser
115 120 125
Val Ser Ser Phe Glu Arg Phe Glu Ile Phe Pro Lys Glu Ser Ser Trp
130 135 140
Pro Asn His Thr Val Thr Gly Val Ser Ala Ser Cys Ser His Asn Gly
145 150 155 160
Lys Ser Ser Phe Tyr Arg Asn Leu Leu Trp Leu Thr Gly Lys Asn Gly
165 170 175
Leu Tyr Pro Asn Leu Ser Lys Ser Tyr Val Asn Asn Lys Glu Lys Glu
180 185 190
Val Leu Val Leu Trp Gly Val His His Pro Pro Asn Ile Gly Asn Gln
195 200 205
Arg Ala Leu Tyr His Thr Glu Asn Ala Tyr Val Ser Val Val Ser Ser
210 215 220
His Tyr Ser Arg Arg Phe Thr Pro Glu Ile Ala Lys Arg Pro Lys Val
225 230 235 240
Arg Asp Gln Glu Gly Arg Ile Asn Tyr Tyr Trp Thr Leu Leu Glu Pro
245 250 255
Gly Asp Thr Ile Ile Phe Glu Ala Asn Gly Asn Leu Ile Ala Pro Trp
260 265 270
Tyr Ala Phe Ala Leu Ser Arg Gly Phe Gly Ser Gly Ile Ile Thr Ser
275 280 285
Asn Ala Pro Met Asp Glu Cys Asp Ala Lys Cys Gln Thr Pro Gln Gly
290 295 300
Ala Ile Asn Ser Ser Leu Pro Phe Gln Asn Val His Pro Val Thr Ile
305 310 315 320
Gly Glu Cys Pro Lys Tyr Val Arg Ser Ala Lys Leu Arg Met Val Thr
325 330 335
Gly Leu Arg Asn Ile Pro Ser Ile Gln Ser Gln Gly Leu Phe Gly Ala
340 345 350
Ile Ala Gly Phe Ile Glu Gly Gly Trp Thr Gly Met Val Asp Gly Trp
355 360 365
Tyr Gly Tyr His His Gln Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp
370 375 380
Gln Lys Ser Thr Gln Asn Ala Ile Asn Cys Ile Thr Asn Lys Val Asn
385 390 395 400
Ser Val Ile Glu Lys Met Asn Thr Gln Phe Thr Ala Val Gly Lys Glu
405 410 415
Phe Asn Lys Leu Glu Arg Arg Met Glu Asn Leu Asn Lys Lys Val Asp
420 425 430
Asp Gly Phe Leu Asp Ile Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu
435 440 445
Leu Glu Asn Glu Arg Thr Leu Asp Phe His Asp Ser Asn Val Lys Asn
450 455 460
Leu Tyr Glu Lys Val Lys Ser Gln Leu Lys Asn Asn Ala Lys Glu Ile
465 470 475 480
Gly Asn Gly Cys Phe Glu Phe Tyr His Lys Cys Asn Asn Glu Cys Met
485 490 495
Glu Ser Val Lys Asn Gly Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu Glu
500 505 510
Ser Lys Leu Asn Arg Glu Lys Ile Asp Gly Val Lys Leu Glu Ser Met
515 520 525
Gly Val Tyr Gln Arg Val Gln Pro Thr Glu Ser Ile Val Arg Phe Pro
530 535 540
Asn Ile Thr Asn Leu Cys Pro Phe Gly Glu Val Phe Asn Ala Thr Arg
545 550 555 560
Phe Ala Ser Val Tyr Ala Trp Asn Arg Lys Arg Ile Ser Asn Cys Val
565 570 575
Ala Asp Tyr Ser Val Leu Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys
580 585 590
Cys Tyr Gly Val Ser Pro Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn
595 600 605
Val Tyr Ala Asp Ser Phe Val Ile Arg Gly Asp Glu Val Arg Gln Ile
610 615 620
Ala Pro Gly Gln Thr Gly Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro
625 630 635 640
Asp Asp Phe Thr Gly Cys Val Ile Ala Trp Asn Ser Asn Asn Leu Asp
645 650 655
Ser Lys Val Gly Gly Asn Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys
660 665 670
Ser Asn Leu Lys Pro Phe Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln
675 680 685
Ala Gly Ser Thr Pro Cys Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe
690 695 700
Pro Leu Gln Ser Tyr Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln
705 710 715 720
Pro Tyr Arg Val Val Val Leu Ser Phe Glu Leu Leu His Ala Pro Ala
725 730 735
Thr Val Cys Gly Pro Lys Lys Ser Thr Asn Leu Val Lys Asn Lys Cys
740 745 750
Val Asn Phe Asn Ile Glu Gly Arg His His His His His His
755 760 765

Claims (8)

1.一种流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原，其特征在于，所述疫苗免疫原为通过在流感病毒血凝素蛋白引入血凝素单体间二硫键半胱氨酸突变，并与新型冠状病毒蛋白RBD结构域进行融合表达获得的重组蛋白。
2.根据权利要求1所述的流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原，其特征在于，所述流感病毒包括但不限于毒株A/Washington/5/2011(H1N1)、毒株A/NewCaledonia/20/1999(H1N1)和与所述毒株A/Washington/5/2011(H1N1)、毒株A/NewCaledonia/20/1999(H1N1)的氨基酸序列具有89％以上同源性的毒株。
3.根据权利要求2所述的流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原，其特征在于，所述毒株A/Washington/5/2011(H1N1)的突变位点L20C-K47C；
所述毒株A/New Caledonia/20/1999(H1N1)的突变位点L24C-G47C。
4.根据权利要求2所述的流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原，其特征在于，所述流感病毒和新型冠状病毒融合重组亚单位疫苗的氨基酸序列如SEQ ID NO:2和SEQ ID NO:4所示。
5.一种流感病毒和新型冠状病毒融合重组蛋白疫苗，其特征在于，所述疫苗包括权利要求1-4任意所述的流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原；
所述疫苗还包括疫苗载体，所述疫苗载体包括：DNA载体、mRNA载体、水凝胶载体、脱溶剂纳米颗粒载体、蛋白质自组装纳米颗粒载体、腺病毒载体、慢病毒载体、植物病毒载体、减毒人感染病毒载体、人感染复制缺陷型病毒载体，以及破伤风类毒素、白喉类毒素、白喉毒素的无毒变异体、B群脑膜炎球菌外膜蛋白复合体、白介素、病原相关分子模式、损伤相关分子模式融合蛋白载体。
6.一种流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原的制备方法，其特征在于，所述制备方法具体包括以下步骤：
将甲型流感病毒HA的信号肽序列进行置换成昆虫细胞蜂毒素信号肽序列，并在HA胞外基因序列的羧基端添加切割位点和亲和纯化标签序列，依据昆虫细胞宿主优化密码子，合成在pFastBac1载体中，获得带有甲型流感病毒HA序列的重组质粒；
在所述带有甲型流感病毒HA序列的重组质粒的HA胞外域基因序列引入单体间半胱氨酸突变获得HA突变体的pFastBac1重组质粒；
将SARS-CoV-2W-1病毒株的S蛋白昆虫细胞表达质粒与所述HA突变体的pFastBac1重组质粒通过Overlap PCR的方法制备融合的昆虫细胞重组表达质粒；
利用bac-to-bac昆虫杆状病毒表达系统表达所述融合的昆虫细胞重组表达质粒并纯化获得HA-RBD重组蛋白。
7.根据权利要求6所述的流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原的制备方法，其特征在于，所述切割位点包括：Factor Xa切割位点、凝血酶裂解位点、HRV 3C蛋白酶切位点、TEV蛋白酶切位点、肠激酶切位点、SUMO蛋白酶切位点；
所述标签序列包括：6×His标签、HA标签、FLAG标签、谷胱甘肽巯基转移酶标签、麦芽糖结合蛋白标签、NusA标签、SUMO标签、Strep-tag标签。
8.根据权利要求6所述的流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原的制备方法，其特征在于，所述利用bac-to-bac昆虫杆状病毒表达系统表达所述融合的昆虫细胞重组表达质粒并纯化获得HA-RBD重组蛋白过程具体包括：
将融合的昆虫细胞重组表达质粒转染sf9昆虫细胞，进行培养获得生长状态良好的细胞后进行扩大培养，离心收集上清液；
将所述上清液进行过滤后，并采用层析亲和树脂进行纯化并进行洗脱置换，获得HA-RBD重组蛋白。
CN202210606093.7A 2022-05-31 2022-05-31 一种流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原及其制备方法 Active CN114773487B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210606093.7A CN114773487B (zh) 2022-05-31 2022-05-31 一种流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210606093.7A CN114773487B (zh) 2022-05-31 2022-05-31 一种流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原及其制备方法

Publications (2)

Publication Number Publication Date
CN114773487A true CN114773487A (zh) 2022-07-22
CN114773487B CN114773487B (zh) 2024-07-02

Family

ID=82420923

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210606093.7A Active CN114773487B (zh) 2022-05-31 2022-05-31 一种流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原及其制备方法

Country Status (1)

Country Link
CN (1) CN114773487B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114752616A (zh) * 2022-05-27 2022-07-15 重庆医科大学 一种表面展示新冠病毒rbd蛋白的类病毒样颗粒及其制备与应用
CN117305365A (zh) * 2023-11-28 2023-12-29 中国科学院生物物理研究所 昆虫细胞—哺乳动物细胞表达穿梭载体SmartBM-1及其应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023421A1 (en) * 1992-05-08 1993-11-25 Smithkline Beecham Corporation Universal coronavirus vaccine
CN105753948A (zh) * 2008-07-08 2016-07-13 麦迪卡格公司 可溶性重组流感抗原
CN112076315A (zh) * 2020-08-25 2020-12-15 中国农业科学院生物技术研究所 新冠病毒s蛋白和铁蛋白亚基融合的纳米抗原颗粒、新冠疫苗及其制备方法和应用
CN112225814A (zh) * 2020-09-29 2021-01-15 东莞博盛生物科技有限公司 一种新型冠状病毒rbd融合蛋白亚单位疫苗及其制备方法和应用
CN113666990A (zh) * 2021-08-24 2021-11-19 复旦大学 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
RU2761879C1 (ru) * 2021-07-27 2021-12-13 Закрытое Акционерное Общество "Биокад" Вакцина на основе AAV5 для индукции специфического иммунитета к вирусу SARS-CoV-2 и/или профилактики коронавирусной инфекции, вызванной SARS-CoV-2
WO2021249013A1 (en) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Vaccine compositions, methods, and uses thereof
CN113801205A (zh) * 2021-09-13 2021-12-17 湖南大学 一种提高甲型流感病毒h1三聚体蛋白抗原性的改造方法
WO2022032660A1 (zh) * 2020-08-14 2022-02-17 武汉友微生物技术有限公司 新型冠状病毒rbd融合蛋白
CN114053403A (zh) * 2020-07-31 2022-02-18 南京优迈生物科技有限公司 融合蛋白在制备疫苗佐剂或预防和治疗病毒感染的药物中的用途

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023421A1 (en) * 1992-05-08 1993-11-25 Smithkline Beecham Corporation Universal coronavirus vaccine
CN105753948A (zh) * 2008-07-08 2016-07-13 麦迪卡格公司 可溶性重组流感抗原
WO2021249013A1 (en) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Vaccine compositions, methods, and uses thereof
CN114053403A (zh) * 2020-07-31 2022-02-18 南京优迈生物科技有限公司 融合蛋白在制备疫苗佐剂或预防和治疗病毒感染的药物中的用途
WO2022032660A1 (zh) * 2020-08-14 2022-02-17 武汉友微生物技术有限公司 新型冠状病毒rbd融合蛋白
CN112076315A (zh) * 2020-08-25 2020-12-15 中国农业科学院生物技术研究所 新冠病毒s蛋白和铁蛋白亚基融合的纳米抗原颗粒、新冠疫苗及其制备方法和应用
CN112225814A (zh) * 2020-09-29 2021-01-15 东莞博盛生物科技有限公司 一种新型冠状病毒rbd融合蛋白亚单位疫苗及其制备方法和应用
RU2761879C1 (ru) * 2021-07-27 2021-12-13 Закрытое Акционерное Общество "Биокад" Вакцина на основе AAV5 для индукции специфического иммунитета к вирусу SARS-CoV-2 и/или профилактики коронавирусной инфекции, вызванной SARS-CoV-2
CN113666990A (zh) * 2021-08-24 2021-11-19 复旦大学 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
CN113801205A (zh) * 2021-09-13 2021-12-17 湖南大学 一种提高甲型流感病毒h1三聚体蛋白抗原性的改造方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ELAHE ALEEBRAHIM-DEHKORDIA等: "T helper type (Th1/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: From cytokines produced to immune responses", TRANSPLANT IMMUNOLOGY, pages 1 - 11 *
李鑫;段广有;张伟;施劲松;陈嘉源;陈舜梅;高山;阮吉寿;: "2019新型冠状病毒S蛋白可能存在Furin蛋白酶切位点", 生物信息学, no. 02, pages 42 - 47 *
王琼;李丹;李金燕;胡冰杰;邱烨;葛行义;: "蝙蝠SARS样冠状病毒WIV1利用小鼠ACE2受体研究", 激光生物学报, no. 02, 15 April 2020 (2020-04-15), pages 28 - 35 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114752616A (zh) * 2022-05-27 2022-07-15 重庆医科大学 一种表面展示新冠病毒rbd蛋白的类病毒样颗粒及其制备与应用
CN117305365A (zh) * 2023-11-28 2023-12-29 中国科学院生物物理研究所 昆虫细胞—哺乳动物细胞表达穿梭载体SmartBM-1及其应用
CN117305365B (zh) * 2023-11-28 2024-03-19 中国科学院生物物理研究所 昆虫细胞—哺乳动物细胞表达穿梭载体SmartBM-1及其应用

Also Published As

Publication number Publication date
CN114773487B (zh) 2024-07-02

Similar Documents

Publication Publication Date Title
CN113929786B (zh) 新型冠状病毒突变株s蛋白及其亚单位疫苗
CN114773487B (zh) 一种流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原及其制备方法
CN111499765B (zh) 一种冠状病毒融合蛋白及其制备方法与应用
CN109311946A (zh) 稳定化的融合前rsv f蛋白
CN109613240B (zh) 一种用于检测hiv的试剂盒
CN102517302A (zh) 一种重组表达水痘-带状疱疹病毒截短型糖蛋白e的方法及其应用
Batra et al. Optimization of conditions for secretion of dengue virus type 2 envelope domain III using Pichia pastoris
CN112010984A (zh) 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白多聚体纳米疫苗
CN113087792B (zh) 一种犬瘟热病毒纳米抗体及其应用
CN113801205B (zh) 一种提高甲型流感病毒h1三聚体蛋白抗原性的改造方法
Arias-Arias et al. Stable production of recombinant SARS-CoV-2 receptor-binding domain in mammalian cells with co-expression of a fluorescent reporter and its validation as antigenic target for COVID-19 serology testing
Postler et al. Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein
CN113832188A (zh) 一种基于荧光蛋白的新型冠状病毒中和抗体快速检测试剂盒及应用
CN109929040B (zh) 一种eb病毒bfrf3-bzlf1融合蛋白、基因、包含其的载体、宿主细胞、试纸条及其生产方法和应用
CN109234302A (zh) 水痘-带状疱疹病毒糖蛋白e基因表达载体及其重组酵母菌株与应用
CN113549634B (zh) 编码可溶性hpv58 l1蛋白的基因及其重组质粒的构建与应用
Wang et al. Mapping the B cell epitopes within the major capsid protein L1 of human papillomavirus type 16
CN115960217A (zh) 一种新型冠状病毒中和活性纳米抗体
CN116041448A (zh) 新型冠状病毒免疫原性物质、其制备方法和应用
CN117327174A (zh) 抗新型冠状病毒人源化多价结合蛋白及其应用
CN113527446A (zh) 一种MERS-CoV S-RBD线性B细胞表位及其特异性识别单克隆抗体和应用
Brudenell et al. Efficient overexpression and purification of severe acute respiratory syndrome coronavirus 2 nucleocapsid proteins in Escherichia coli
CN114805564B (zh) 特异性识别SARS-CoV-2 S蛋白NTD区域的单克隆抗体及应用
CN114751964B (zh) β属冠状病毒通用疫苗蛋白片段及其筛选方法和应用
CN110903356B (zh) 一种猪圆环病毒ii型抗原以及检测猪圆环病毒ii型抗体的胶体金免疫层析试纸条

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant